Zelluna submits UK clinical trial application and publishes preclinical data for ZI-MA4-1 cell therapy for solid tumours
CTA submission to the UK MHRA and peer-reviewed preclinical results mark Zelluna’s transition into the clinic, with first-in-human data for ZI-MA4-1 expected in mid-2026